A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 7, 2017

Study Completion Date

August 9, 2018

Conditions

Adenocarcinoma of the Prostate

Interventions

DRUG

Pazopanib

Pazopanib, 800 mg, orally daily for 28 days prior to radical prostatectomy.

OTHER

Placebo

Placebo tablet orally, daily for 28 days prior to radical prostatectomy.

Trial Locations (1)

Huntsman Cancer Institute, Salt Lake City